neurology today

Mice given calcitonin gene-related peptide (CGRP), a migraine trigger, lost their aversion to light when given the two main components of cannabis, tetrahydrocannabinol (THC) and cannabidiol (CBD) simultaneously. , according to a study published in American Headache. Annual scientific meeting of the society.

At the same time, the cannabinoid-treated mice showed no impairment of their motor function when tested in the rotarod test.

“Our preclinical studies add to the growing body of supporting literature indicating that cannabinoids can help relieve migraine symptoms at well-tolerated doses,” said the paper’s senior author, Andrew F. Russo, PhD, a professor in the department of molecular physiology. & biophysics and in the department of neurology at the University of Iowa.

“While these results are preliminary and still need to be verified, we believe our findings warrant further study of these compounds in human trials,” said Dr. Russo.

Erik Zorrilla, a graduate student in Dr. Russo’s lab, presented the findings at the meeting.

To conduct their study, the research teams co-administered CGRP at 0.1 mg/kg along with THC, CBD, and combinations of the two. Positive control mice received only CGRP, and negative controls received only the sunflower oil in which the other drugs were administered.

Cannabinoids had no effect on light aversion in mice that did not receive CGRP. But when CGRP with CBD and THC was administered, their aversion to light “was almost completely alleviated… and was no longer significantly different from the negative control group.”

Mice were placed on a stationary rotarod test bar for three trials of five minutes each, separated by 10 minutes of rest. During each five-minute test, the bar would start spinning at a rate of four rotations per minute, eventually increasing to 60 RPM. The researchers then measured how long it took for the mice to fall off the bar.

For a positive control, the group used diazepam (5 mg/kg), and for a negative control, they used only sunflower oil.

They found that none of the cannabinoid combinations affected the mice’s motor function. “The data showed that at the 100:1 ratio (CBD to THC), we were able to reverse the light aversion phenotype,” Zorilla said.

In an email, Dr. Russo said, “If confirmed in humans, a similar product would have the potential to offer relief to millions of migraine sufferers.”

The THC and CBD used in the study were provided by Schedule 1 Therapeutics, and the study was funded by the National Institutes of Health and the Migraine Research Foundation.

While he was impressed with the mouse model of migraines, a leading migraine specialist said he was concerned that people might interpret the wrong message from the newspaper.

“The utility of this article is not to suggest that people with migraines go without THC,” said Peter Goadsby, MD, PhD, DSc, professor of neurology at the David Geffen School of Medicine at UCLA and director of the National Research Institute in Medical Care. Wellcome Trust at King’s College Clinical Research Center in London. “It’s about having a model that is sensitive to pharmacology, using light aversion as a surrogate in an experimental animal.”

Dr. Goadsby called Dr. Russo a “pioneer who has championed this model. He is highly respected.” But, said Dr. Goadsby, he is concerned about the possible harmful effects of cannabinoids.

“The cannabinoid receptors are located in the same place in the brain as the opioid receptors,” he said. “What we have learned over the last 50 years is that giving opioids to people with migraines on a regular basis is a spectacularly bad idea. , it pays to be careful with this kind of pharmacology.”

“Cannabinoids, at the very least, don’t help, and in the people I see, they tend to hinder improvement,” Dr. Goadsby said.

Zorrilla had no disclosures. Dr. Russo disclosed that he has received funding from the National Institutes of Health, the Veterans Administration Medical Center, the Migraine Research Foundation, and Lundbeck, and has consulted for Lundbeck, AbbVie, Eli Lilly, Amgen/Novartis and Schedule 1 Therapeutics. .

Link for more information

AHS OR-03: Zorrilla E, Kuburas A, Wattiez A, et al. Therapeutic potential of cannabinoids in preclinical models of migraine.

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button